Michael Siekman focuses his practice on intellectual property matters, including patent prosecution, licensing and post-grant proceedings and litigation. Leveraging over 25 years of experience, Michael has built in-depth patent portfolios, advising clients in the biotechnology and pharmaceutical industries.
Michael keeps clients’ business goals in mind as he regularly provides legal counsel in the litigation matters, including Hatch-Waxman matters, and post-grant solutions for biosimilars. He has successfully led matters before the Patent Trial and Appeal Board (PTAB) and the European Patent Office. His licensing practice involves IP-related aspects of mergers, acquisitions, IPOs and other financing and licensing programs.
Lead counsel in two IPRs defending BTG International’s patent covering its antibody product. Obtained termination of IPR with parallel ITC proceeding and denial of institution of second IPR*
Lead counsel in four IPRs defending four Cold Spring Harbor Laboratory patents relating to short hairpin RNA (shRNA). Obtained denial of institution of all four IPRs, preserving Cold Spring Harbor’s widely licensed shRNA patent portfolio*
Lead counsel in interference for Dyax against Adimab. Invalidated Adimab’s patent and obtained patent to same invention by proving 11 months of diligence*
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.